All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Clinical Efficacy of Edaravone and Urinary Kallidinogenase Co-Treatment in Acute Ischemic Stroke

Author(s): Xiaoxiao Pan*, Xiaoqian Gong, Lili Pan and Liyu Lu
Department of Neurology, 1Department of Ultrasound Diagnosis, The First People???s Hospital of Yancheng, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, Jiangsu 224006, China

Correspondence Address:
Xiaoxiao Pan, Department of Neurology, The First People???s Hospital of Yancheng, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, Jiangsu 224006, China, E-mail: ycyypxx@163.com


To evaluate the clinical effectiveness of utilizing edaravone in conjunction with uric acid in treating acute ischemic stroke. Between January 2021 and January 2023, 120 individuals with acute ischemic stroke were admitted to the neurology department of our hospital and were subsequently divided into the observation group and the control group through random assignment. Edaravone monotherapy was utilized in the control group, while the observation group received a combination treatment of edaravone and uric acid. Prior to treatment and post-treatment, the levels of high-sensitivity C-reactive protein and tumor necrosis factor-alpha in the bloodstream were analyzed, while also documenting the overall effective rate and the occurrence of adverse reactions. Post-treatment, a considerable decline was observed in national institutes of health stroke scale and activities of daily living scores for both groups in comparison to their respective pre-treatment scores. Furthermore, the observation group displayed significantly lower national institutes of health stroke scale and activities of daily living scores compared to the control group after treatment, with a p<0.05. The observation group exhibited a remarkably higher overall effective rate compared to the control group, with statistical significance (p<0.05). Additionally, post-treatment, the levels of inflammatory factors in the observation group were notably lower as opposed to the control group. There was no statistically significant distinction in the incidence of adverse reactions between the two groups (p>0.05). The co-administration of edaravone and uric acid in treating acute ischemic stroke may effectively mitigate brain tissue damage by modulating the body's inflammatory response. As a result, it facilitates neurological recovery and enhances the daily living abilities of patients. The significant advantages derived from this treatment approach underscore the importance of promoting its implementation.

Full-Text | PDF

 
 
Google scholar citation report
Citations : 61564

Indian Journal of Pharmaceutical Sciences received 61564 citations as per google scholar report